Verition Fund Management
LXEO icon

Verition Fund Management’s Lexeo Therapeutics LXEO Stock Holding History

Verition Fund Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-428,458
Closed -$4.25M – 3031
2025
Q4 		$4.25M Buy
428,458
+13,595
+3% +$124K 0.02% 993
2025
Q3 		$2.75M Hold
414,863
– – 0.01% 1707
2025
Q2 		$1.67M Hold
414,863
– – 0.01% 2080
2025
Q1 		$1.44M Sell
414,863
-295,037
-42% -$1.31M 0.01% 1825
2024
Q4 		$4.67M Sell
709,900
-67,420
-9% -$531K 0.02% 932
2024
Q3 		$7.03M Buy
777,320
+355,928
+84% +$4.24M 0.04% 618
2024
Q2 		$6.76M Buy
421,392
+360,549
+593% +$5.24M 0.04% 547
2024
Q1 		$954K Sell
60,843
-128,219
-68% -$2.01M 0.01% 1647
2023
Q4 		$2.54M Buy
+189,062
New +$2.35M 0.02% 727

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verition Fund Management's LXEO Position: Q1 2026 in Review

Verition Fund Management sold out of Lexeo Therapeutics (LXEO) in Q1 2026, closing a stake of 428,458 shares — an estimated $4.25M sold.

Verition Fund Management first reported a position in LXEO in Q4 2023 and held it in 9 quarters. The position peaked at $7.03M in Q3 2024. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • Verition Fund Management reported no remaining Lexeo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 428,458 Lexeo Therapeutics shares in Q1 2026, an estimated $4.25M.
  • Verition Fund Management first reported a position in Lexeo Therapeutics in Q4 2023 and held it in 9 quarters.
  • Verition Fund Management's Lexeo Therapeutics position peaked at $7.03M in Q3 2024.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.